Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
11,898 total articles
Adrian W. Quartel, Chief Medical Officer of Zevra Therapeutics (ZVRA), sold 4,533 shares on January 30, 2026, for about $40,035 at a weighted average price of $8.8321. The transactions recorded on a Form 4 also show the grant of restricted stock units and options and the exercise of options to acquire additional shares. Zevra's stock trades above t…
KeyCorp Chief Human Resources Officer Angela G. Mago sold 62,850 shares of KeyCorp common stock on January 29, 2026, for a total of $1.35 million, at prices between $21.54 and $21.55. On the same day she exercised options to acquire 62,850 shares at $10.49, for a total of $659296. After the transactions, Mago directly holds 261,415 shares, a figure…
John Taylor Maloney Fitzgerald, President and CEO of Kingsway Financial Services Inc., purchased 183 shares at $13.69 on February 2, 2026, for $2,505 through the company ESPP. The transaction raises his direct holdings to 1,460,086 shares. The purchase coincides with a 70% one-year share gain and recent third-quarter 2025 revenue growth, but Invest…
Palomar Holdings NASDAQ:PLMR Chief People Officer Timothy Carter sold 254 restricted stock units on January 29, 2026 for $122.0415 per share, generating $30,998. The transaction coincided with the vesting of 610 RSUs and was carried out to satisfy minimum statutory tax withholding. Separately, Palomar reported a robust third quarter for 2025, beat …
Brian Birchler, Executive Vice President, Corporate and Development Operations at Ionis Pharmaceuticals, sold 6,179 shares on January 30, 2026, for about $513,047, while having acquired 11,991 shares the day prior through vesting of performance-based restricted stock units. The transaction occurred as IONS traded close to its 52-week high of $86.15…
Mark N. Tompkins, a reported 10% owner of Aeluma, Inc. (ALMU), sold a total of $1.53 million in common stock across several trades executed between January 29 and February 2, 2026. The transactions covered a range of prices from $15.74 to $17.16. After the disposals, Tompkins retains direct ownership of 1,824,988 Aeluma shares. ALMU is trading at $…
Patrick R. O’Neil, Executive Vice President, CLO and General Counsel of Ionis Pharmaceuticals, sold 6,179 shares on January 30, 2026, for about $516,153 and recorded the vesting of 11,991 performance-based restricted stock units the prior day. The transactions leave O’Neil with 71,983 shares. Separately, Ionis disclosed recent regulatory and clinic…
Eric Swayze, executive vice president of research at Ionis Pharmaceuticals, sold 6,179 shares on January 30, 2026, for about $512,446. The transaction occurred as Ionis shares trade near a 52-week high and follow a separate vesting-related acquisition of 11,991 shares on January 29. The moves come alongside regulatory approvals, positive clinical d…
Ionis Pharmaceuticals CEO Brett P. Monia sold roughly $5.2 million worth of company shares on January 30, 2026, after receiving a larger grant the prior day from vested performance-based restricted stock units. The stock is trading near its 52-week high, supported by recent regulatory approvals and positive Phase 3 trial results, while company fina…
Eugene Schneider, executive vice president and chief clinical development officer at Ionis Pharmaceuticals (IONS), sold 6,179 shares on January 30, 2026, for $515,629, after receiving 11,991 performance-based restricted stock units that vested a day earlier. The sale occurred at prices close to the stock’s 52-week high, while the company has seen s…
PubMatic CEO Rajeev K. Goel sold a combined 65,592 shares of Class A Common Stock in late January and early February 2026 for roughly $477,250. The trades included transactions executed through The Goel Family Trust under a Rule 10b5-1 plan. Separately, Goel exercised options and converted Class B shares into Class A shares. PubMatic also reported …
Charles R. Schwab, Co-Chairman of Charles Schwab Corporation (NYSE: SCHW), sold 145,650 shares on January 29, 2026, for roughly $15 million at a weighted average price of $103.1649. The transaction leaves him with substantial direct and indirect holdings. The firm also announced a 19% dividend increase and an internal leadership change at Charles S…
Solid Biosciences Inc. Chief Financial Officer Kevin Tan sold 26,837 shares of common stock on February 2, 2026, in a set of transactions that generated about $172,747. The disposition, reported on a Form 4, was executed to meet withholding tax obligations tied to the recent vesting of performance stock units. The company continues to report clinic…
Nextpower Inc director William D. Watkins sold 5,000 shares on January 30, 2026, for $118.57 per share, a transaction totaling $592,850. The sale, reported in a Form 4 filing with the Securities and Exchange Commission, occurred with the stock trading close to its 52-week high and after the company posted fiscal third-quarter results that outperfor…
Palomar Holdings' CEO and chairman Mac Armstrong sold 7,604 shares across January 29 and 31, 2026, for about $927,354 at a weighted average price between $121.7437 and $122.0432. Simultaneously, Armstrong received 14,771 restricted stock units through option exercises at no cost. The insurer reported a strong third quarter for 2025, beating EPS and…
American International Group Executive Vice President and CFO Keith Walsh disclosed dividend reinvestment purchases of AIG common stock totaling $2,207 between December 2024 and December 2025, with share prices between $73.20 and $86.54. Walsh also disposed of 4,540 shares at $73.92 for $335,596 and now directly holds 42,799.25 shares. Separately, …
Jon Christianson, president of Palomar Holdings Inc (NASDAQ: PLMR), sold 1,673 restricted stock units on January 29 and 31, 2026, for roughly $204,025 and concurrently exercised options that converted to 4,109 shares at no cost. The company, a specialty insurer with a $3.29 billion market value, has shown robust revenue growth and recent acquisitiv…
TD Synnex director Richard T. Hume sold 492 shares on January 30, 2026, for $78,921 and exercised options to acquire 492 shares at $107.32 the same day. The trades were carried out under a Rule 10b5-1 plan adopted July 14, 2025. Separately, TD Synnex reported fourth-quarter 2026 net revenue of $17.4 billion and non-GAAP diluted EPS of $3.83, while …
Yelp Chief Executive Jeremy Stoppelman disposed of 90,000 shares of common stock across three transactions between January 29 and February 2, 2026, generating roughly $2.46 million. The trades were carried out under a pre-arranged 10b5-1 plan adopted May 19, 2025, coinciding with option exercises and ahead of Yelp's February 12 earnings report. The…
Power Integrations director Balu Balakrishnan completed an automatic sale of 5,581 shares on January 29, 2026, generating $260,036 to cover taxes on a Restricted Stock Award. The transaction was reported on a Form 4 filed February 2, 2026. Separately, the company increased the share pool for its 2025 Inducement Award Plan and saw mixed analyst sign…
Kent A. Hansen, chief financial officer and executive vice president of Kingsway Financial Services Inc., purchased 114 shares at $13.69 apiece on February 2, 2026, using the company’s employee share purchase plan. The $1,560 transaction modestly increased Hansen’s direct holdings to 119,707 shares. The move comes as Kingsway reports strong revenue…
PACCAR Inc. Senior Vice President Laura J. Bloch sold 6,588 shares of common stock on February 2, 2026, for $814,088, while simultaneously exercising options to acquire 6,588 shares at $61.26 per share. The transactions occurred as the stock traded close to its 52-week high, and follow the company’s mixed fourth-quarter 2025 results that featured a…
Assured Guaranty Ltd. and affiliated entities reported the sale of 237 Sound Point Meridian Capital (NASDAQ: SPMC) shares on January 29, 2026, for $3,393, according to a Form 4 filed with the SEC. The submission, executed on February 2, 2026, documents the internal ownership structure of the selling entities and confirms that they continue to hold …
Axsome Therapeutics CEO Herriot Tabuteau sold 32,410 shares on February 2, 2026, for roughly $6.0 million after exercising options to buy the same number of shares at $8.02 each. The transactions occurred while AXSM traded close to its 52-week high and follow strong revenue momentum and multiple analyst target increases amid pipeline progress.
Zevra Therapeutics President and CEO Neil F. McFarlane sold 91,000 shares on February 2, 2026, for about $853,425, following option exercises and recent equity awards. The company recently reported mixed third-quarter 2025 results and announced an expanded access distribution agreement for its Miplyffa program, with H.C. Wainwright maintaining a Bu…
